An Open-Label, Single Dose Study to Assess the Breast Milk and Plasma Pharmacokinetics of Omaveloxolone (BIIB141) in Healthy Lactating Women
Latest Information Update: 08 Nov 2024
Price :
$35 *
At a glance
- Drugs Omaveloxolone (Primary)
- Indications Brain disorders; Friedreich's ataxia; Malignant melanoma; Mitochondrial disorders; Ocular inflammation; Ocular pain
- Focus Pharmacokinetics
- Sponsors Reata Pharmaceuticals
- 05 Nov 2024 Status changed from not yet recruiting to recruiting.
- 30 Sep 2024 New trial record